While many companies use viruses and viral vectors to deliver gene therapy and to modify cells for CAR T treatments, others have shunned adeno-associated viruses (AAV) and lentiviral vectors for other methods to deliver DNA and RNA into the cells.

By priming CAR T cells through antigen delivery to the lymph node, researchers have boosted the responses of CAR T cells to solid tumor antigens.